SITE006 (GBR) › SITE006-0254

SITE006-0254

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2026-06-26

enrolled

AEs

Serious

Dropout signal

–

Adverse events

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-02 (study day 55); relationship: not assessed

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-15 (study day 40); relationship: NOT RELATED

mild assessed

Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-01-19 (study day 13); relationship: not assessed; serious criteria: hospitalization

severe serious assessed

Data queries

No data queries. Open queries would appear here for this patient.